M Moriyama

No ORCID on file · 8 papers in corpus · active 1985-2016

Study types

  • article 7
  • other 1

Condition tags

  • endometriosis 7
  • adenomyosis 1
article 2016
ORIGINAL ARTICLE Reproductive biology Enhanced

miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3

article 2014
DR6 is epigenetically involved in the pathogenesis of endometriosis by creating the proliferative and anti-apoptotic characteristics
·doi:10.1016/j.jri.2014.09.026
article 2014
Enhanced miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3
Human Reproduction ·doi:10.1093/humrep/deu332

STUDY QUESTION: What are the roles of the microRNA miR-210-an miRNA that is up-regulated in endometriotic cyst stromal cells (ECSCs)-in the pathogenesis of endometriosis? SUMMARY ANSWER: Up-regulated miR-210 expression in ECSCs is involved …

article 2010
Differential Diagnosis of Ovarian Cancer, Benign Ovarian Tumor and Endometriosis by a Combination Assay of Serum Sialyl SSEA-1 Antigen and CA125 Levels
Gynecologic and obstetric investigation ·doi:10.1159/000293304

We used a combination assay of serum sialyl SSEA-1 antigen (SLX) and CA125 levels, and evaluated the clinical usefulness of this technique for a differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis. In 82 patient…

other 1990
Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease
Gynecologic and obstetric investigation ·doi:10.1159/000293386

Sialyl SSEA-1 antigen (SLX) is a highly specific tumor marker composed of sugar chain antigens that have Lewis X at their terminals and bind to sialic acid. This antigen is rarely detected in normal tissues, and is present in adenocarcinoma…

article 1989
[Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels].
Nihon Gan Chiryo Gakkai shi

We used a combination assay of serum sialyl SSEA-1 antigen (SLX) and CA125 levels, and evaluated the clinical usefulness of this technique for a diagnosis of ovarian cancer and follow-up of the patient with ovarian cancer. In 28 patients wi…

article 1986
Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer —A study on 674 patients—
The Japanese journal of surgery ·doi:10.1007/bf02470551
article 1985
[Differential diagnosis between leiomyomata uteri and adenomyosis using CA 125 as a new tumor marker of ovarian carcinoma].
Nihon Sanka Fujinka Gakkai zasshi

To differentiate pre-operatively between leiomyomata uteri and adenomyosis, we measured serum levels of an antigen (CA 125) common to most nonmucinous epithelial ovarian carcinoma in patients with benign uterine tumor (11 of leiomyomata ute…